Dr. Urban A Kiernan is the Founder, Chairman and CEO of iMetabolic Biopharmam Corporation.
With over 20 years of industry business and research experience, Urban A. Kiernan, PhD is the Founder, Chairman and CEO of iMetabolic Biopharma Corporation, iMBP, an early stage techbio company that is developing innovative computation technologies to streamline drug discovery and support its current therapeutic pipeline of 5 drugs. Dr. Kiernan is a seasoned leader who has already raised more than $1.75 Million in startup investment for iMBP from a broad spectrum of sources including angels, NIH grants and Strategic corporate partners. Most notable are the partnership deals with Ligand Pharmaceuticals, now OmniAb, via spin out and Amazon Web Services.
Prior to starting iMBP, Dr. Kiernan was the Director of Biomarker Discovery at Intrinsic Bioprobes Inc, during which time he was the recipient of several Phase I & II National Institutes of Health grants, negotiated a significant licensing deal with Johnson & Johnson, and was able to achieve his first business exit through acquisition to Thermo Fisher Scientific. He then later worked for Thermo Fisher Scientific and was able to rise through the ranks in Global Business Development, providing him a breadth of knowledge and experience in the life science and biopharma sectors while developing critical leadership skills. He is a graduate of Arizona State University, receiving his PhD in Bio-Analytical Chemistry in 2002.
iMetabolic Biopharmam Corp Website – https://imbiopharma.com/
iMetabolic Biopharmam Corp Facebook – https://www.facebook.com/iMBPCorp
iMetabolic Biopharmam Corp LinkedIn – https://www.linkedin.com/company/imetabolic-biopharma-corporation/
iMetabolic Biopharmam Corp Urban A Kiernan PhD – https://www.linkedin.com/in/urban-a-kiernan-ph-d-8568b621/
iMetabolic Biopharmam Corp Instagram – https://www.instagram.com/imetabolic_biopharma/
iMetabolic Biopharmam Corp Urban Kiernan PhD – https://www.instagram.com/light_bearer/
iMetabolic Biopharmam Corp X (Twitter) – https://twitter.com/iMetabiopharma
